

Chemotherapy

TREATMENT MODALITIES

- Surgery
- Radiotherapy
- Systemic therapies:
 - Chemotherapy
 - Hormonal therapy
 - Immunotherapy
 - Biological (targeted) therapies

Systemic Anti-cancer therapies (SACT)

- Cancer is a "systemic" disease - roughly 50% patients will develop metastatic disease
- Systemic therapy (drug therapy - cytotoxic agents, hormones, biologics) distributes widely through the body - normal and malignant tissues
- Local therapy (surgery, radiation) is directed to a defined area of documented or presumed disease

Goals of SACT

Systemic therapy can be given for:

- Cure
- Increase survival
- Palliate symptoms through disease control
- Neoadjuvant / induction treatment - when local treatment is insufficient and disease is proven to be disseminated beyond the scope of local therapy
- Adjuvant / preventive treatment - when there is a high risk of recurrence with local treatment alone

Goals of SACT

Uses of cancer drugs

To **cure** some tumours **even** when they are disseminated or metastatic

as an **adjuvant**, i.e., after all clinically apparent disease has been resected (surgery), in order to eliminate or suppress the growth of occult cancer cells that have already metastasized (micrometastasis), ultimately increasing overall survival (colon, breast, lung)


used in **combination with radiation** therapy to **shrink** the tumour burden in order to permit surgery, to control systemic disease, or both or to permit organ preservation

If cure is not possible, chemotherapy may be undertaken with the goal of **palliating** some aspect of the tumour's effect on the host

SACT

- Systemic therapy is based on the biology of cancer.
- Types of systemic therapy:
 - Cytotoxic agents (chemotherapy) eg Cisplatin, Etoposide
 - Targeted therapy , eg Gefitinib (tyrosine Kinase Inhibitors)
 - Endocrine/hormonal, eg Tamoxifen
 - Biologic therapies, eg Interferon

Types of drugs used in cancer treatment



Who gets SACT?

Factors to consider:

- Tumour factors
 - Stage
 - Pathological features
 - Treatment intent
- Patient factors
 - Fitness for treatment
 - Co-morbidity
 - Patient wishes

Fitness for treatment

Performance status:

- An attempt to quantify patients' wellbeing

Scoring systems:

- Karnofsky score
- WHO/ECOG score

WHO/ECOG score

0 - Asymptomatic

Fully active, able to carry on all activities without restriction

1 - Symptomatic

Ambulatory, able to carry out light work eg light housework

2 - Symptomatic

Up >50% of day, capable of all self care but unable to carry out any work activities

3 – Symptomatic

>50% of day in bed but not bedbound (limited self-care)

4 - Bedbound

Completely confined to bed/chair; incapable of self care

Chemotherapy

- The aim of chemotherapy is *“to do the maximum damage to cancer cells while causing the minimum damage to healthy tissue.”*
- It is the use of cytotoxic drugs to destroy cancer cells
- Chemotherapy affects the entire body.
- This in combination with it affecting both healthy and cancer cells means it can be quite aggressive.
- However it is used widely today because of its ability to reduce and even eliminate cancer.


THE IDEAL **TARGET** FOR CANCER THERAPY

- Has a high level of expression in neoplastic tissues
- Plays a fundamental role in the pathogenesis of the cancer
- Does not have a vital role in normal tissues
- Target activation (eg phosphorylation) correlates well with its function
- Can be inhibited pharmacologically
- Target inhibition results in anti-tumor effects

THE IDEAL AGENT FOR CANCER THERAPY

- Has a high specificity and affinity for its target
- Interaction with target results in anti-tumor effects
- Has predictable and consistent pharmacological attributes
- Has minimal normal tissue toxicity
- Agent is easy to administer and ideally suitable for chronic administration e.g. oral use
- Potential application in either prevention or therapy of cancer

*There are over 50 different
cytotoxic drugs available*



HOW DOES CHEMOTHERAPY WORK?

- Tumour cells have poor DNA repair mechanisms
- Normal cells can repair or replace themselves more efficiently
- Intermittent chemotherapy damages **both** normal replicating cells **and** tumour cells but the tumour cells do not recover as quickly
- DNA damage may prevent production of daughter cells or cause cell death eg through induction of apoptosis

Action sites of cytotoxic agents




TABLE 1: Cell-cycle-phase-specific drugs**S phase-dependent**

Antimetabolites

Capecitabine
Cytarabine
Doxorubicin
Fludarabine
Flouxuridine
Fluorouracil
Gemcitabine
Hydroxyurea
Mercaptopurine
Methotrexate
Prednisone
Procarbazine
Thioguanine

M phase-dependentVinca alkaloids²

Vinblastine
Vincristine
Vinorelbine

Podophyllotoxins

Etoposide
Teniposide

Taxanes

Docetaxel
Paclitaxel

G₂ phase-dependent

Bleomycin
Irinotecan
Mitoxantrone
Topotecan

G₁ phase-dependent

Asparaginase
Corticosteroids

² Have greatest effects in S phase and possibly late G₂; cell blockade or death, however, occurs in early mitosis.

Adapted, with permission, from Dorr RT, Von Hoff DD (eds): *The Cancer Chemotherapy Handbook*, 2nd ed, p 5. East Norwalk, Connecticut, Appleton & Lange, 1993.

CLASSIFICATION OF CYTOTOXIC AGENTS

ALKYLATING AGENTS	ANTI-METABOLITES	MITOTIC INHIBITORS	ANTIBIOTICS	OTHERS
BUSULFAN	CYTOSINE	ETOPOSIDE	BLEOMYCIN	L-ASPARAGINASE
CARMUSTINE	ARABINOSIDE	TAXOIDS	DACTINOMYCIN	HYDROXYUREA
CHLORAMBUCIL	FLOXURIDINE	VINBLASTINE	DAUNORUBICIN	PROCARBAZINE
CISPLATIN	FLUOROURACIL	VINCRISTINE	DOXORUBICIN	
CYCLOPHOSPHAMIDE	MERCAPTOPURINE	VINDESINE	MITOMYCIN-C	
IFOSFAMIDE	METHOTREXATE		MITOXANTRONE	
MELPHALAN			PLICAMYCIN	

ANTI-TUMOUR ANTIBIOTICS

- Actinomycin, Mitomycin C, Bleomycin.
- Fungal in origin
- Fragment DNA and form free radicals
- Work throughout cell cycle
- Used in testicular and haematological cancers and sarcomas

Doxyrubicin and epirubicin are anthracycline antibiotics that are both cardiotoxic

Bleomycin is a non-anthracycline antibiotic but unlike **Mitozantrone** and **Mitomycin C** it does not cause significant bone marrow suppression.

ALKYLATING AGENTS

- The first cytotoxic drugs, includes cyclophosphamide and ifosfamide which are still used today
- Cross link DNA by binding irreversibly to the N7 atoms of guanine bases
- Main action is during the synthesis phase of cell cycle
- Synthetic drugs using reactive Pt species work similarly:
Cisplatin, Carboplatin and Oxaliplatin
- Cause both intra- and inter- DNA strand linkage of guanine bases and prevent DNA splitting
- Used in many solid and haematological tumours

Alkylating agents:

- **Cyclophosphamide**
- **Chlorambucil**
- **Melphalan**


Non-classical alkylating agents

- **Cisplatin**
- **Carboplatin**

ANTI-METABOLITES


- Prevent synthesis of purines or pyrimidines which are required for formation of both DNA and RNA
- Similar in structure to natural metabolites
- Work in S phase of the cell cycle
- Examples : **Methotrexate, 5-Fluorouracil, Gemcitabine**
- Used in colorectal, breast and pancreatic cancers.

ANTI-METABOLITES




VINCA ALKALOIDS

- Derived from the periwinkle plant
- Bind to tubulin (building block of cell spindles)
- Cause metaphase arrest (in mitotic part of cell cycle)
- Examples : Vincristine, Vinblastine, Vinorelbine,
Vinflunine
- Used in haematological, lung and breast cancers



**Inhibition by
vinca alkaloids
and taxanes**

Chemotherapy side effects



Hand-foot syndrome





Chemotherapy extravasation



Allergic reaction



Mucositis


Toxicity Prevention

- Prophylactic anti-emetics
 - Vascular access devices minimize extravasation
 - Adequate pre/post hydration
 - Stop below known toxic cumulative doses
 - Dose reduction / delay
 - Growth factor support
 - Prophylactic antibiotics
 - Mouth care
 - Cytoprotectants / rescue agents
-
- Maintain a high index of suspicion and intervene early!



Why does chemotherapy fail?

- **Primary resistance.**
 - Tumour is not sensitive to selected treatment
- **Secondary resistance.**
 - Tumour becomes resistant to a treatment which originally caused a response
 - Natural selection (Darwinian theory)

competing tumour cells



chemotherapy.



resistant cell replicates
free from competition




sensitive to
treatment.



resistant to
treatment.

RELAPSE VERSUS CURE






**LIVER METS:
BEFORE
CHEMO**




**LIVER
METS:
PARTIAL
RESPONSE
ON CHEMO**

LIVER AFTER RESECTION OF METASTASIS



**LIVER METS:
BEFORE
CHEMO**



**LIVER METS:
PROGRESSION
ON
CHEMO**



Natural Selection Of Resistance

- Cancer cells originate from cellular mutations that prevent normal control of division
- Since tumour cells are unstable further mutations probable
- Some mutations may allow some of the tumour cells to resist cytotoxics. (around 10^8 cells dividing)

Mechanisms Of Resistance

- Alterations in cell membrane
- Increased drug deactivation
- Loss of drug activation
- Increased production of target molecule(s)
- Change in enzyme specificity
- Production of non-essential competitors, (decoys)
- Alternative Biochemical pathways
- Increased repair of damage to DNA

HOW TO AVOID RESISTANCE

- Treat when tumour is small (less likely to contain resistant cells)
- Use combinations of chemotherapy that are non-cross resistant and have different toxicity profiles:
eg cisplatin and 5-fluorouracil
 - Alkylating agent to damage DNA
 - Anti-metabolite to prevent DNA synthesis and repair
- Use effective doses of chemotherapy drugs eg optimal supportive care to allow maintenance of dose intensity

IMMUNOTHERAPY: INTERFERONS

- Powerful immunomodulatory effects but also anti-metastatic and anti-angiogenic effects and are cytostatic and cytotoxic to some tumour cells
- Bind to receptors and signal transduction pathways cause induction of interferon target genes
- Effects on both innate and adaptive immune system
- Used systemically in melanoma, renal cell cancer, HIV-related Kaposi's sarcoma, hairy cell leukaemia, CML and Non-Hodgkins-lymphoma
- Used intra-vesically in TCC bladder
- Toxicities include flu-like symptoms, fatigue and depression

WHAT MONOCLONAL ANTIBODIES ARE IN USE TODAY?

- Herceptin (1998, targets Her-2, used in breast cancer)
- Avastin (2005, targets VEGF itself, used in CRC)
- Erbitux (2006, targets EGFR, mostly humanised, used in CRC and SCC H&N)
- Panitumumab (2007, targets EGFR, fully humanised, used in CRC)
- Many more in development

Key points – chemotherapy

- Docetaxal is a Taxane.
- Vinca alkaloids are highly vesicant.
- Chlorambucil is an alkylating agent that does not characteristically cause alopecia.
- Carboplatin is a non-classical alkylating agent that has a better side effect profile than Cisplatin (which is ototoxic and causes peripheral neuropathy, renal failure). However carboplatin causes marked bone marrow suppression.
- Palma plantar syndrome is an erythematous skin lesion of the palmar and plantar of the hand and feet is most often caused by cytostatic chemotherapy: 5FU is the main culprit.
- Methotrexate is an anti-metabolite that is associated with bone marrow suppression.